StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.14+0.04 (+0.17%)

Close on Nov 18, 2026Market cap $463.06MP/E –Yield –

Neurogene operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Neurogene's operating income for the twelve months ending Jun 30, 2026 was -$121.35M. For fiscal 2025 it was -$103.33M. The highest annual figure on record is -$32.62M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$103.33M–
FY2024Dec 31, 2024-$82.61M–
FY2023Dec 31, 2023-$55.58M–
FY2022Dec 31, 2022-$56.52M–
FY2021Dec 31, 2021-$60.70M–
FY2020Dec 31, 2020-$33.73M–
FY2019Dec 31, 2019-$70.96M–
FY2018Dec 31, 2018-$32.62M–
FY2017Dec 31, 2017-$51.12M–
FY2016Dec 31, 2016-$37.65M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$36.67M–
Q1 FY2026Mar 31, 2026-$33.35M–
Q4 FY2025Dec 31, 2025-$27.53M–
Q3 FY2025Sep 30, 2025-$23.80M–
Q2 FY2025Jun 30, 2025-$26.08M–
Q1 FY2025Mar 31, 2025-$25.92M–
Q4 FY2024Dec 31, 2024-$21.51M–
Q3 FY2024Sep 30, 2024-$22.18M–
Q2 FY2024Jun 30, 2024-$20.13M–
Q1 FY2024Mar 31, 2024-$18.78M–
Q4 FY2023Dec 31, 2023-$14.73M–
Q3 FY2023Sep 30, 2023-$15.22M–
Q2 FY2023Jun 30, 2023-$12.60M–
Q1 FY2023Mar 31, 2023-$13.04M–
Q4 FY2022Dec 31, 2022-$11.67M–
Q3 FY2022Sep 30, 2022-$13.61M–
Q2 FY2022Jun 30, 2022-$15.87M–
Q1 FY2022Mar 31, 2022-$15.37M–
Q4 FY2021Dec 31, 2021-$15.17M–
Q3 FY2021Sep 30, 2021-$15.45M–
Q2 FY2021Jun 30, 2021-$15.12M–
Q1 FY2021Mar 31, 2021-$14.95M–
Q4 FY2020Dec 31, 2020-$12.64M–
Q3 FY2020Sep 30, 2020-$2.25M–
Q2 FY2020Jun 30, 2020-$9.77M–
Q1 FY2020Mar 31, 2020-$9.07M–
Q4 FY2019Dec 31, 2019-$8.36M–
Q3 FY2019Sep 30, 2019-$59.52M-2312.5%
Q2 FY2019Jun 30, 2019-$428.00K–
Q4 FY2018Dec 31, 2018-$5.30M–
Q3 FY2018Sep 30, 2018-$15.20M–
Q2 FY2018Jun 30, 2018$2.69M–
Q4 FY2017Dec 31, 2017-$16.53M–
Q3 FY2017Sep 30, 2017-$12.07M–
Q2 FY2017Jun 30, 2017-$14.00M–

More Neurogene figures

See a number that looks wrong?